Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts

Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts
Atossa Therapeutics advances DMD research

Sandra Hammer, PhD, of Atossa Therapeutics, Inc. is set to deliver an oral presentation at the MDA Clinical and Scientific Conference.

Her research outlines how (Z)-Endoxifen restores muscle performance and reduces damage biomarkers in Mdx5cv dystrophic mice, marking a promising preclinical advance for Duchenne muscular dystrophy therapies. The presentation is scheduled for March 11th at 9:00 AM EST. The event will gather scientific and clinical experts to discuss recent progress in muscular dystrophy research.

Hammer’s latest findings on (Z)-Endoxifen’s therapeutic potential in Duchenne muscular dystrophy build upon Atossa Therapeutics’ broader efforts to advance precision endocrine therapies. This work underscores the company’s ongoing commitment, as detailed in their recent progress on the Z-endoxifen platform targeting both oncology and DMD with molecular precision. Further context on the framework for risk reduction in breast cancer using Z-Endoxifen can be found in the company’s comprehensive strategy for prevention.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.